March 8, 2024
Stemson Therapeutics and Aderans Company, the parent company of Bosley and HAIRCLUB, today announced an agreement securing Stemson the exclusive global rights to research, develop, and commercialize hair regeneration therapeutic products based on Aderans’ proprietary hair regeneration cell therapy technology. Stemson will resume Aderans’ Phase 2 clinical stage cell therapy hair regeneration program, integrate the technology into its existing hair loss cell therapy development pipeline, and provide multiple products for patients experiencing hair loss.
See the press release
Read More »
February 16, 2024
Kevin D’Amour, Stemson’s Chief Scientific Officer, speaks with Cell & Gene Therapy Insights about developing an iPSC-derived cell therapy solution to engineer follicular units to treat hair loss.
Read the interview
Read More »
February 6, 2024
Stemson Therapeutics announced today the promotion of Meghan Samberg, PhD, to Chief Development Officer, and Nick Wisniewski, PhD, to Vice President Data Sciences and Bioinformatics. The promotions move Stemson firmly into the final stages of product development with an emphasis on leveraging bioengineering, big data, and machine learning approaches to create a highly controlled and reproducible therapeutic outcome for hair growth.
See the press release
Read More »
February 6, 2024
Stemson Therapeutics today announced a major technological advance that clears the path for its proprietary hair rejuvenation solution to advance toward human clinical trials. Stemson is developing an iPSC-derived autologous cell therapy to regenerate healthy hair follicles and has successfully created human hair follicles in humanized mice using engineered follicular units (EFUs). The EFUs are designed to provide an unlimited source of hair follicle replacements capable of treating a range of hair loss indications, including Androgenetic Alopecia,
Read More »
February 1, 2023
Stemson Therapeutics announced today that Kevin D’Amour has joined the company as Chief Scientific Officer. Kevin has 20 years of experience in cell therapy development, and spent ten years as Chief Scientific Officer at ViaCyte. While at Viacyte, Kevin took three stem cell-derived cell therapy products into the clinic to treat Type 1 Diabetes.
See the press release
Read More »
November 30, 2022
Stemson’s Vice President of R&D, Meghan Samberg, speaks about Stemson’s solution for hair follicle regeneration at the World Congress for Hair Research in Melbourne, Australia. See Link
Read More »
October 28, 2022
Geoff Hamilton, CEO, recently spoke with The Science Advisory Board at the Alliance for Regenerative Medicine’s annual Meeting On The Mesa.
See the interview
Read More »
April 18, 2022
Stemson Therapeutics announced today that Paul Laikind, serial entrepreneur and former CEO of cell therapy company ViaCyte, has joined the Stemson Board of Directors. Paul brings significant company building and therapeutics development experience to the Stemson Board.
See the press release
Read More »
February 1, 2022
Stemson Therapeutics announced today the addition of Kapil Bharti, Ph.D. and George Murphy, M.D. to its Scientific Advisory Board. The addition of these distinguished leaders in the field significantly bolster Stemson’s efforts to restore human hair growth with a novel cell regeneration technology using the patient’s own cells to generate new hair follicles. Dr. Bharti is a Senior Investigator at the National Eye Institute at the National Institutes of Health and is a world renowned expert in regenerative medicine,
Read More »
December 2, 2021
Stemson Therapeutics has been chosen as Select Technology Contributor at the 2021 Global Hair Loss Summit (GHLS). GHLS is the premier virtual educational and networking event in the field of surgical hair restoration and all associated modalities. Founder and CEO Geoff Hamilton has been given the honor to present a keynote address entitled “Developing Induced Pluripotent Stem Cell Technology to Engineer a De Novo Supply of Hair Follicles to Treat Hair Loss.”’ Mr.
Read More »
